AIMP3对非小细胞肺癌脑转移的影响
方洋1 熊绍风1 罗海海2 潘德城1 赵欣怡1 胡建兰1（通讯作者）

1南昌大学第一附属医院药学部，江西南昌，330006；

2南昌大学第一附属医院呼吸与危重症医学科，江西南昌，330006；

摘要：目的：探究AIMP3对非小细胞肺癌脑转移的影响。方法：采用CCK8测定细胞存活率；采用细胞划痕测定细胞增殖复制能力；采用Western blot法测定血脑屏障通透性相关抑制蛋白（ZO-1、Occludin和Claudin-5）表达；采用RT-qRCR法测血脑屏障通透性相关抑制mRNA（ZO-1、Occludin和Claudin-5）水平；采用血脑屏障（BBB）模型与迁移结合实验测定细胞迁移功能。结果：过表达AIMP3（转染HA-AIMP3）处理A549细胞24 h后，A459细胞活力显著降低（P<0.05），细胞增殖复制能力显著降低（P<0.05），血脑屏障通透性相关抑制蛋白和mRNA表达水平显著升高，细胞迁移能力降低（P<0.05）。结论：体外实验表明，AIMP3具有抑制非小细胞肺癌细胞穿透血脑屏障及转移的潜力。

关键词：AIMP3；非小细胞肺癌；脑转移；血脑屏障

参考文献

[1]Zuo L, Zou X, Ge J, et al. The Nrf2-HMOX1 pathway as a therapeutic target for reversing cisplatin resistance in non-small cell lung cancer via inhibiting ferroptosis. Cell Death Discov. 2025;11(1):287.

[2]Zungsontiporn N, Srianuwattipong K, Santisukwongchote S, et al. The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment. Sci Rep. 2025;15(1):30989.

[3]Zou Z, Wu L, Hao X, et al. Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer. Thorac Cancer. 2025;16(2):e70000.

[4]Zou FW, Shi SH, Wu C, et al. circ_PPAPDC1A is Associated with Brain Metastasis of Non-Small-Cell Lung Cancer via the miR-30a-3p/SPOCK1 Pathway. Ann Surg Oncol. 2025.

[5]Zhou L, Li Z, Zhou S, et al. Targeting NAD + biosynthesis suppresses TGF-β1/Smads/RAB26 axis and potentiates cisplatin cytotoxicity in non-small cell lung cancer brain metastasis. Acta Neuropathol Commun. 2025;13(1):56.

[6]Zhao S, Zhang H. Key genes associated with brain metastasis in non-small cell lung cancer: novel insights from bioinformatics analysis. Front Bioinform. 2025;5:1625664.

[7]Zhang X, Zhang X, Yin H, et al. Roles of SPOCK1 in the Formation Mechanisms and Treatment of Non-Small-Cell Lung Cancer and Brain Metastases from Lung Cancer. Onco Targets Ther. 2025 Jan 16;18:35-47.

[8]Zhang Q, Yang Y, Xie M, et al. Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases. Lung Cancer. 2025;205:108616.

[9]Zhou C, Yang Y, Cui H, et al. SEC61G Facilitates Brain Metastases via Antagonizing PGAM1 Ubiquitination and Immune Microenvironment Remodeling in Non-Small Cell Lung Cancer. Int J Biol Sci. 2025;21(4):1436-1458.

[10]Zhang Q, Chen K, Yu X, et al. Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives. Int J Cancer. 2024;155(12):2117-2128.

[11] Xie M, Qin H, Liu L, et al. GABA regulates metabolic reprogramming to mediate the development of brain metastasis in non-small cell lung cancer. J Exp Clin Cancer Res. 2025;44(1):61.

[12]Zhu L, Yang F, Wang G, et al. CXC Motif Chemokine Receptor Type 4 Disrupts Blood-Brain Barrier and Promotes Brain Metastasis Through Activation of the PI3K/AKT Pathway in Lung Cancer. World Neurosurg. 2022;166:e369-e381.

[13]Zhou Q, Yu Y, Xing L, et al. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial. Med. 2025;6(1):100513.

[14]Tajes M, Ramos-Fernández E, Weng-Jiang X, et al.The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol Membr Biol. 2014;31(5):152-67.

[15]熊绍风,熊小伟,彭国平,等.鸢尾素激活PGC-1α、UCP-1促进噬脂和褐变抑制 ACHN细胞增殖和迁移[J].重庆医学,2024,53(03):321-327.

[16]熊绍风,李炜,邱雪峰,等.芹菜素改善高糖高脂应激所致血管内皮细胞功能失调的机制研究[J].南昌大学学报(医学版),2024,64(06):27-32+72.